| Patents for A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128) |
|---|
| 05/16/2002 | US20020058064 Flavored gelatin capsule and method of manufacture |
| 05/16/2002 | US20020058063 Stable pharmaceutical dosage form for paroxetin anhydrate |
| 05/16/2002 | US20020058061 Pharmaceutical dosage form for pulsatile delivery of methylphenidate |
| 05/16/2002 | US20020058058 Transdermal compositions containing low molecular weight drugs which are liquid at room temperatures |
| 05/16/2002 | US20020058057 Brachytherapy seed |
| 05/16/2002 | US20020058055 Oil-containing biliquid foam dispersed in a salt-containing aqueous phase having a pH of less than about 7, is gelled by a polymeric sulfonic acid, e.g., ammonium acrylamidopropanesulfonic acid-vinylformamide copolymer |
| 05/16/2002 | US20020058050 Treating pain by administering 24 hours opioid formulations exhibiting rapid rise of drug level |
| 05/16/2002 | US20020058048 Contains a nonionic, amphoteric or cationic surfactant in an amount effective to eliminate or substantially ameliorate burning pain caused by capsaicin. |
| 05/16/2002 | US20020058047 Vaccines |
| 05/16/2002 | US20020058040 Injectable vaccine composition comprising an immunogenic conjugate in a water in oil emulsion; enhanced immunogenicity after storage at about -18 degrees C. |
| 05/16/2002 | US20020058035 Reducing FSH levels by administering a GnRH antagonist to reduce both plasma FSH and LH levels; treating prostatic intraepithelial neoplasia, pedophilia, infertility, vaginal bleeding; in vitro fertilization and male contraception |
| 05/16/2002 | US20020058021 Plasmid containing a nucleotide sequence encoding an immunogen of a pathogen to allow in vivo expression of this sequence, and as a cationic lipid, 2,3-di-c12-18-alkoxy-N-(amino- or hydroxyalkyl)-N,N-dimethylpropylammonium salt |
| 05/16/2002 | US20020058009 Pulmonary delivery in treating disorders of the central nervous system |
| 05/16/2002 | DE10145134A1 Komplexe zur Einführung von Nukleinsäuren in Zellen Complex for the introduction of nucleic acids into cells |
| 05/16/2002 | DE10056136A1 Inhibiting leukocyte or tumor cell adhesion to vascular endothelial cells e.g. for combating inflammation or metastasis, using e.g. pregnancy proteins or selectin binding liposomes containing calcium-binding compound |
| 05/16/2002 | DE10048510A1 Lagerstabile Infusionslösung des Ciprofloxacins mit verringertem Säuregehalt A storage-stable infusion of ciprofloxacin with reduced acidity |
| 05/16/2002 | CA2429012A1 New pharmaceutical compositions based on tiotropium salts and salts of salmeterol |
| 05/16/2002 | CA2428784A1 Oral pharmaceutical composition containing a block copolymer |
| 05/16/2002 | CA2428181A1 Pharmaceutical preparation of percutaneous absorption type |
| 05/16/2002 | CA2428179A1 Compositions of n-(methylethylaminocarbonyl)-4-(3-methylphenylamino)-3-pyridylsulfonamide and cyclic oligosaccharides |
| 05/16/2002 | CA2428159A1 Delayed-release pharmaceutical formulations containing proinsulin c-peptide |
| 05/16/2002 | CA2428141A1 Use of selectin-binding pregnancy proteins, liposomes, native mucin fragments and mimetic compounds for the treatment and prophylaxis of inflammatory diseases, for preventing metastatic spread and for the prophylaxis of tumour diseases |
| 05/16/2002 | CA2428114A1 Apolipoprotein analogues |
| 05/16/2002 | CA2427283A1 Device and method for the cessation of smoking |
| 05/16/2002 | CA2425688A1 Extended release erythromycin derivatives |
| 05/16/2002 | CA2425594A1 Compositions containing hydrolytically unstable compounds |
| 05/15/2002 | EP1205191A1 Targeted modification of intracellular compounds |
| 05/15/2002 | EP1205190A1 Stable medicinal compositions for oral use |
| 05/15/2002 | EP1205181A2 Composition and method for parenteral administration of ibuprofen D, L-or L-Lysine salt |
| 05/15/2002 | EP1205180A2 Delivery system for hydrophobic drugs |
| 05/15/2002 | EP1205177A2 Conjugate, method for its production and use thereof |
| 05/15/2002 | EP1204761A2 Targeted artificial gene delivery |
| 05/15/2002 | EP1204744A1 Isolated peptide of the horny layer and use thereof |
| 05/15/2002 | EP1204635A1 Branched, largely unsaturated fatty alcohol ether sulphates |
| 05/15/2002 | EP1204634A2 Branched, substantially unsaturated fatty alcohol sulfates |
| 05/15/2002 | EP1204630A1 Branched, substantially unsaturated ester oils |
| 05/15/2002 | EP1204627A1 Branched, largely unsaturated fatty alcohol polyglycolethers |
| 05/15/2002 | EP1204595A1 Polytype mg-ai hydrotalcite |
| 05/15/2002 | EP1204434A1 Tissue augmentation material and methods |
| 05/15/2002 | EP1204430A2 Conjugates and methods for the production thereof, and their use for transporting molecules via biological membranes |
| 05/15/2002 | EP1204429A2 Sustained release formulation of a peptide |
| 05/15/2002 | EP1204428A2 Targeted lipid particles |
| 05/15/2002 | EP1204427A1 The nasal transmucosal delivery of peptides conjugated with biocompatible polymers |
| 05/15/2002 | EP1204423A1 Therapeutic antibody against muc-1 antigen and methods for their use |
| 05/15/2002 | EP1204417A2 Parenteral cisplatin emulsion |
| 05/15/2002 | EP1204409A1 Microparticles for pulmonary administration |
| 05/15/2002 | EP1204407A2 Implantable active ingredient depot |
| 05/15/2002 | EP1204406A2 Opioid sustained-released formulation |
| 05/15/2002 | EP1102594B1 Use of sodium chloride to reduce the gastrointestinal toxicity of camptothecin derivatives |
| 05/15/2002 | EP1054686B1 Pharmaceutical formulation of a didemnin compound |
| 05/15/2002 | EP1032391B1 Spheroids containing tiagabine, preparation process and pharmaceutical compositions |
| 05/15/2002 | EP0688329B1 Novel phospholipid-saccharide conjugates |
| 05/15/2002 | EP0626850B1 Dry compositions for preparing submicron emulsions |
| 05/15/2002 | CN1349543A Membrane disruptive peptides covalently oligomerized |
| 05/15/2002 | CN1349526A Prodrugs of thrombin inhibitors |
| 05/15/2002 | CN1349418A Compositions for treatment of disorders of the oesophagus |
| 05/15/2002 | CN1349409A Metabolic intervention with GLP-1 to improve the function of ischemic anc reperfused tissue |
| 05/15/2002 | CN1349408A Pegylated interferon alfa-CCR5 antagonist combination HIV therapy |
| 05/15/2002 | CN1084616C Coatings for tablet of paracetamol and domperidone |
| 05/15/2002 | CN1084614C Medicaments |
| 05/15/2002 | CN1084595C Utilizations of edible oil |
| 05/14/2002 | US6388112 Using solvent, active charcoal, ion exchange resin; evaporation |
| 05/14/2002 | US6388053 Mixing glucagon-like peptide-1 with a divalent metal cation, then incubating to form a complex; antidiabetic agents |
| 05/14/2002 | US6388047 Hydrophobic, hydrophilic macromolecules |
| 05/14/2002 | US6387918 A tricyclic compound (with oxy and nitrogen atoms in the ring); perticularly useful for treating or preventing psoriasis and other skin diseases |
| 05/14/2002 | US6387917 Nasal administering |
| 05/14/2002 | US6387884 Modulate binding of leukocyte to endothelial cells; antiinflammatory agents |
| 05/14/2002 | US6387876 Covalent polar lipid-conjugates with biologically active compounds for use in salves |
| 05/14/2002 | US6387695 DNA pharmaceutical formulations comprising citrate or triethanolamine and combinations thereof |
| 05/14/2002 | US6387663 Fusion protein of collagen binding domain and angiogenesis modulating domain; treatment of cardiovascular disorders; antiischemic agents |
| 05/14/2002 | US6387409 Composition and method of preparing microparticles of water-insoluble substances |
| 05/14/2002 | US6387408 Adhesive drug delivery composition |
| 05/14/2002 | US6387407 Topical drug preparations |
| 05/14/2002 | US6387406 Copolymer compositions for oral delivery |
| 05/14/2002 | US6387403 Dosage forms and methods for providing effective reboxetine therapy with once-a-day dosing |
| 05/14/2002 | US6387400 Process for preparing pharmaceutical compositions for use with soft gelatin formulations |
| 05/14/2002 | US6387395 N-[1, (1-1) -dialkyloxy] - and N- [1, (1-1) -dialkenyloxy]- alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor |
| 05/14/2002 | US6387394 Controlled release insufflation carrier for medicaments |
| 05/14/2002 | US6387390 Compositions and methods for enhancing receptor-mediated cellular internalization |
| 05/14/2002 | US6387383 Topical low-viscosity gel composition |
| 05/14/2002 | US6387371 Specifically binds to an extracellular domain of the her2 receptor in an amount effective to inhibit growth of cancer cells |
| 05/14/2002 | US6387363 Absorbable sutures; synthetic lactic acid and glycolic acid copolylactone; each successive monomer can be specifically specified; cell-free translation system; synthetic messenger ribonucleic acid (mrna) as a template |
| 05/14/2002 | US6387359 N-long chain acylamino acid polyglycerin esters; cosmetics |
| 05/14/2002 | US6387355 A sunscreen formulation comprising a hydroxybenzophenones absorbing in the ultraviolet-a region and uv-b region absorber is selected from dibenzoyl, benzotriazole, triazine, benzimidazole, tetrahydroxybenzophenone or organosiloxane |
| 05/14/2002 | US6387350 Utilizing a labeled single chain antibody fragment or subfragment with a molecular weight of 85,000 daltons or less that specifically binds to an antigen produced by or associated with tumors or lesions |
| 05/14/2002 | CA2361160A1 Composition and method for parenteral administration of ibuprofen d,l- or l-lysine salt |
| 05/14/2002 | CA2263905C Chlorofluorocarbon-free mometasone furoate aerosol formulations |
| 05/14/2002 | CA2234235C Gel formulations containing growth factors |
| 05/14/2002 | CA2205771C Improved delivery of disease modifiers |
| 05/14/2002 | CA2179540C Accelerated release composition containing bromocriptine |
| 05/14/2002 | CA2167090C Compositions and methods for stimulating megakaryocyte growth and differentiation |
| 05/14/2002 | CA2104678C Protein-induced morphogenesis |
| 05/14/2002 | CA2089742C Methods and compositions for early detection and treatment of insulin dependent diabetes mellitus |
| 05/14/2002 | CA2086323C Functionally active selectin-derived peptides and ligand for gmp-140 |
| 05/14/2002 | CA2033418C Pharmaceutical preparation for oral administration in fluid form |
| 05/14/2002 | CA2032499C Polypeptide derivatives |
| 05/14/2002 | CA2028234C Cellulosic coating |
| 05/10/2002 | WO2002036771A2 Imaging, diagnosis and treatment of disease |
| 05/10/2002 | WO2002036767A2 Therapeutic oligonucleotides of reduced toxicity |
| 05/10/2002 | WO2002036628A2 New multimeric interferon beta polypeptides |